Welcome to our dedicated page for Staar Surg SEC filings (Ticker: STAA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The STAAR Surgical Company (NASDAQ: STAA) SEC filings page on Stock Titan brings together the company’s official disclosures from the U.S. Securities and Exchange Commission. STAAR is a medical device manufacturer focused on ophthalmic surgery, and its filings provide detailed information on its implantable intraocular lens business, corporate actions, and governance.
Investors can review Current Reports on Form 8-K in which STAAR reports material events, such as the August 2025 Agreement and Plan of Merger with Alcon, subsequent amendments, the go-shop process, adjournments of special meetings of stockholders, and later communications about the failure to obtain shareholder approval and the intended termination of the merger agreement. Other 8-K filings describe litigation related to the merger proxy statement, preliminary and final financial results, and leadership changes, including the appointment of a Chief Financial Officer and the creation of a Capital Stewardship Committee of the Board.
Filings also confirm that STAAR’s common stock is listed on Nasdaq under the symbol STAA and document how the proposed merger, if completed, would have affected listing status and registration. By reading these documents, users can trace the evolution of STAAR’s strategic transaction with Alcon, the role of major shareholders in the process, and the company’s decision to remain a standalone, publicly traded entity after the merger was not approved.
On Stock Titan, STAAR’s SEC filings are updated as new documents are released on EDGAR. AI-powered tools summarize lengthy filings such as 8-Ks and related exhibits, helping users quickly identify key terms, conditions, and outcomes without reading every page. This makes it easier to track transaction terms, board and management changes, and other disclosures that shape the outlook for STAA within the ophthalmic medical device industry.
STAAR Surgical and major shareholder Broadwood Partners entered a cooperation agreement that reshapes the company’s board and clarifies the Broadwood group’s status. Broadwood Partners and Broadwood Capital report beneficial ownership of 15,453,629 shares each, or about 31.1% of the 49,741,953 shares outstanding as of October 31, 2025. Neal C. Bradsher may be deemed to beneficially own 15,479,529 shares, also about 31.1% of the class.
The agreement leads to two directors resigning, three new directors being appointed (including Bradsher and Richard T. LeBuhn) and nominated for election at the 2026 annual meeting. Broadwood agrees not to request a special shareholder meeting, including to remove directors, until June 18, 2026, and both sides provide mutual releases and non‑disparagement commitments.
STAAR Surgical Co received an updated ownership filing from a group of investment entities connected to Yunqi and HS Group. The largest reported position is 3,257,130 shares of common stock, representing 6.5% of the class, beneficially owned by Yunqi Capital Limited, Yunqi Capital Cayman Limited, Christopher Min Fang Wang, and related entities. Other entities in the group, including Yunqi Path Capital Master Fund and Yunqi China Special Investment A, report additional share holdings, with Yunqi Path Capital Master Fund alone reporting 2,575,061 shares, or 5.2% of the class. The amendment also notes that on January 14, 2026, STAAR Surgical entered into a cooperation agreement with Broadwood Partners, L.P., under which Christopher Min Fang Wang was appointed to the company’s Board of Directors effective that same date.
STAAR Surgical Company reported several corporate governance changes centered on its Board of Directors. Effective January 15, 2026, the Board elected Neal C. Bradsher as Board Chair. Bradsher is the founder and president of Broadwood Capital, Inc., whose affiliate Broadwood Partners, L.P. is currently the company’s largest stockholder.
The Board restructured its three standing committees so that the Audit, Compensation, and Nominating and Governance committees are each composed entirely of independent directors. STAAR notified NASDAQ that it has regained compliance with the Audit Committee independence requirements under NASDAQ Listing Rule 5605, so it is no longer operating under a cure period.
The Board also created two new committees: a Search Committee to help guide decisions on company leadership, including identifying a successor to the Chief Executive Officer, and an Insight and Engagement Committee to strengthen engagement with management, stakeholders, and industry experts. Non-employee directors, including the new Board Chair, will be eligible for compensation for these roles under the existing director compensation program.
STAAR Surgical Company entered a cooperation agreement with major stockholder Broadwood Partners, L.P., leading to significant board and leadership changes. The Board size increased from six to seven directors, two directors, including CEO and director Stephen C. Farrell and director Elizabeth Yeu, MD, resigned from the Board, and three new directors, Neal C. Bradsher, Richard T. LeBuhn and Christopher Min Fang Wang, were appointed and will be nominated for election at the 2026 annual meeting. Mr. Farrell will step down as Chief Executive Officer effective January 31, 2026, or earlier as determined by the Board, and will provide consulting services for one year at
STAAR Surgical director Wei Jiang reported the vesting and conversion of restricted stock units into common shares. On January 12, 2026, 20,967 restricted stock units granted on May 12, 2025 vested and were converted into 20,967 shares of STAAR Surgical common stock at an exercise price of $0 per share. These units were the final third of an award that vested in three equal installments on August 12, 2025, November 12, 2025, and January 12, 2026. Following this transaction, Jiang directly beneficially owned 66,444 shares of STAAR Surgical common stock.
Broadwood Partners, L.P., a 10% owner of STAAR Surgical, reported buying 27,485 shares of common stock on January 9, 2026 at a weighted average price of $22.0534 per share, bringing its directly owned stake to 15,453,629 shares.
These shares are held by Broadwood Partners and may be deemed indirectly beneficially owned by Broadwood Capital, Inc. and its president, Neal C. Bradsher, who also directly owns 25,900 shares of STAAR Surgical common stock.
Broadwood Partners, L.P., a 10% owner of STAAR Surgical Co. (STAA), reported open‑market purchases of the company’s common stock in early January 2026. Broadwood Partners bought 186,946 shares at a weighted average price of $21.0111 and 150,000 shares at $22.3756 on January 6, followed by 66,467 shares at $22.0004 on January 7 and 3,240 shares at $21.9389 on January 8. After these transactions, Broadwood Partners reported holding 15,426,144 shares of STAAR Surgical common stock. A separate holding of 25,900 STAAR Surgical shares is reported as being directly owned by Neal C. Bradsher. The filing notes that Broadwood Capital, Inc. and Neal C. Bradsher may be deemed indirect beneficial owners through their roles with Broadwood Partners, but each disclaims beneficial ownership except to the extent of any pecuniary interest.
STAAR Surgical’s major shareholders updated their ownership report in this amended Schedule 13D. A group of Yunqi- and HS-branded entities, together with individual investor Christopher Min Fang Wang, disclose beneficial ownership of STAAR Surgical common stock based on 49,751,953 shares outstanding as of October 31, 2025.
Yunqi Path Capital Master Fund reports beneficial ownership of 2,575,061 shares, representing 5.2% of the company. Yunqi Capital Limited, Yunqi Capital Cayman Limited and Mr. Wang each report beneficial ownership of 3,257,130 shares, or 6.5% of the outstanding stock. Yunqi China Special Investment A and several HS Group entities each report beneficial ownership of 682,069 shares, or 1.4%.
The filing states that share purchases, totaling up to tens of millions of dollars across the reporting entities, were funded from working capital, with no dedicated borrowing other than ordinary-course working capital. On January 8, 2026, the reporting persons also entered into a Joint Filing Agreement to coordinate their Schedule 13D filings.
STAAR Surgical Company reported that its planned merger with Alcon Research, LLC has been terminated in accordance with the merger agreement, effective January 6, 2026. No termination fee will be paid by STAAR, Alcon, or the merger subsidiary, and each party will cover its own costs and expenses related to the proposed transaction.
On the same date, STAAR held a special stockholder meeting to vote on proposals related to the merger. Of 49,365,823 shares of common stock outstanding as of the October 24, 2025 record date, 43,367,928 shares, or about 87.9% of the voting power, were represented, establishing a quorum. Stockholders did not approve the merger proposal, with 14,904,915 votes for, 27,339,877 against, and 1,123,136 abstentions, and also did not approve the merger-related compensation proposal, with 14,224,065 votes for, 27,905,792 against, and 1,238,071 abstentions.
STAAR Surgical Company reported that it held a special meeting of stockholders on January 6, 2026 to consider proposals related to its Agreement and Plan of Merger with Alcon Research, LLC and Rascasse Merger Sub, Inc. The merger agreement was originally dated August 4, 2025 and had been amended on November 7, 2025 and December 9, 2025. The company stated that it issued a press release announcing the preliminary voting results from this special meeting, which is included as Exhibit 99.1 to the report.
FAQ
What is the current stock price of Staar Surg (STAA)?
What is the market cap of Staar Surg (STAA)?
